-
NCCN 2025: Advancing Breast Cancer Risk Assessment and Prevention Strategies
02 Apr 2025 01:50 GMT
… presentation during the National Comprehensive Cancer Network (NCCN) 2025 … advancements in breast cancer (BC) risk … the near-term breast cancer risk,” Sardesai … Tools for Breast Cancer Risk Assessment.” National Comprehensive Cancer Network Annual Conference …
-
Healthcare Resource Utilization and Cost Comparison Between Palbociclib, Abemaciclib, and Ribociclib Among Patients with HR+/HER2− Metastatic Breast Cancer
25 Mar 2025 19:05 GMT
… V.3.2023. © National Comprehensive Cancer Network, Inc. 202X. All … therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5 … HER2-negative metastatic breast cancer. NPJ Breast Cancer. 2023;9(1 … 47;HER2- metastatic breast cancer. NPJ Breast Cancer. 2022;8(1 …
-
Targeted Axillary Dissection Offers a Precise Option in Breast Cancer
12 Mar 2025 19:10 GMT
… allowing surgeons to accurately stage breast cancer, Dr. Kandace P. McGuire … staging in patients undergoing breast cancer treatment, highlighting what benefits … to our national guidelines, the National Comprehensive Cancer Network Guidelines — which are [what …
-
Knowledge, Attitude, and Practice Towards Rehabilitation in Patients with Breast Cancer: A Cross-Sectional Study
11 Mar 2025 15:41 GMT
… in Oncology (NCCN Guidelines). Breast Cancer. Version 4.2023. National Comprehensive Cancer Network; 2023.
4. Senkus … Oncology (NCCN Guidelines). Breast Cancer Risk Reduction. Version 1.2023. National Comprehensive Cancer Network; 2022.
6 …
-
HER2+ Early Breast Cancer: Tailoring Therapy in the Era of Expanding Options
08 Mar 2025 00:43 GMT
… to the 2024 National Comprehensive Cancer Network Guidelines, regardless of … strategies for HER2+ breast cancer: neoadjuvant and adjuvant … node negative HER2+ breast cancer. NPJ Breast Cancer. 2024;10(1): … HER2-positive early breast cancer after neoadjuvant …
-
Advancing Care for Metastatic Breast Cancer: Oncology Pharmacists Tackle Innovation, Biomarkers, and Operational Hurdles
28 Feb 2025 20:40 GMT
… ESR1-mutated metastatic breast cancer (MBC) management … National Comprehensive Cancer Network (NCCN), are crucial to help standardize biomarker testing recommendations for breast cancer … with advanced breast cancer with ESR1 … just in breast cancer either, so …
-
Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
26 Feb 2025 12:25 GMT
…
HR-positive breast cancer
Breast cancer is the … hormone receptor‑positive breast cancer. Breast Cancer Res. 2021; … Estrogen receptor positive breast cancers have patient specific … -30898-0.
National Comprehensive Cancer Network. Clinical Practice Guidelines …
-
IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
31 Mar 2025 11:11 GMT
… , NSCLC, bladder cancer, breast cancer, several gastrointestinal and gynecologic … 2021;1-94.
NCCN, National Comprehensive Cancer Network® (NCCN®). Referenced with permission … Cancer Version 7.2024.© National Comprehensive Cancer Network, Inc. [2025]. All …
-
KN026-Docetaxel Combo Shows Efficacy, Safety in HER2+ Metastatic Breast Cancer
17 Feb 2025 19:02 GMT
… paper.
According to the National Comprehensive Cancer Network Breast Cancer Clinical Practice Guidelines, … positive recurrent/metastatic breast cancer is pertuzumab (Perjeta) … HER2-positive recurrent-metastatic breast cancer. Subsequent large, randomized …
-
Development and Validation of a Predictive Model for Anxiety Trajectories in Patients with Breast Cancer: A Retrospective Study
14 Feb 2025 21:12 GMT
… breast cancer. TNM staging was conducted based on the National Comprehensive Cancer Network … diagnosed with breast cancer often exhibit … post-surgical breast cancer patients. Breast Cancer Res Treat. … -positive metastatic breast cancer receiving trastuzumab …
About
© 1995-2025